Archive | Uncategorized

UMB Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development

PumasAI

Company spun out of University of Maryland School of Pharmacy provides a sophisticated pharmaceutical modeling and simulation platform with upgraded Productivity and Compliance Suites BALTIMORE, Aug. 16, 2021 /PRNewswire/ — Pumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development […]

Comments Off on UMB Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development Continue Reading →

BioBuzz: Cartesian Therapeutics Pipeline Showcased Among Cutting-Edge Therapies in BioHealth Capital Region

Cartesian Logo New JPG

Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum. The Strengths of our Region: Cutting Edge Therapies panel, which was moderated by Mark Cobbold, vice president of Discovery in […]

Comments Off on BioBuzz: Cartesian Therapeutics Pipeline Showcased Among Cutting-Edge Therapies in BioHealth Capital Region Continue Reading →

GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo

GlycoT

BALTIMORE, Sept. 14, 2020 /PRNewswire/ — GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.daiichisankyo.com). The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB […]

Comments Off on GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo Continue Reading →

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs

Maxcyte logo square

Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement. Under the agreement, […]

Comments Off on MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs Continue Reading →

GEn1E Lifesciences Granted Exclusive License for UMB Drug Portfolio Compound

umventures-logo-trans

PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and all-fields license to the University of Maryland, Baltimore’s (UMB) specific and function selective p38a kinase inhibitor program. GEn1E is developing cures […]

Comments Off on GEn1E Lifesciences Granted Exclusive License for UMB Drug Portfolio Compound Continue Reading →

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer

Maxcyte logo square

– Clinical and commercial agreement using MaxCyte’s recently launched ExPERT™ platform – Takes MaxCyte’s total number of partnered commercial licenses to seven CAMBRIDGE, Mass. & GAITHERSBURG, Md., (November 21, 2019)— Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences […]

Comments Off on Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer Continue Reading →

Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965

Indalo

Demonstrates strong safety and oral PKData presented November 7, 2019 at PFF Summit, San Antonio, TX Cambridge, MA, November 11, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), for the first time presented clinical data […]

Comments Off on Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965 Continue Reading →

Capital M Podcast: KaloCyte President & CEO Elaine Haynes Discusses Business in Maryland

Kalocyte

The Capital M Podcast #LifeScienceRevolution: Proximity to Resources with KaloCyte. Listen to part 3 of the Capital M podcast, #LifeScienceRevolution: Proximity to Resources with KaloCyte. In this episode, MTC CEO Martin Rosendale discusses business in Maryland with Elaine E. Hayne, President and CEO of KaloCyte, Inc., a pre-clinical biotech startup developing a synthetic red blood cell substitute. Listen to the […]

Comments Off on Capital M Podcast: KaloCyte President & CEO Elaine Haynes Discusses Business in Maryland Continue Reading →

Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis

Cartesian Logo New JPG

First CAR-T to enter clinical development for an autoimmune disease Descartes-08 engineered to have a defined, predictable half-life, enabling repeat dosing to maximize potential for potency while minimizing risk of toxicity Gaithersburg, MD, November 5, 2019 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer and autoimmune diseases, today […]

Comments Off on Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis Continue Reading →

BioBuzz: Pat Larrabee is Building the Biotech Infrastructure in the Capital Region and has been for Nearly 25 Years – Here’s What’s Next…

Pat2

The growth of the BioHealth Capital Region (BHCR) and its position as a global biohealth cluster is a hot topic of discussion—often filtered through a broad, conceptual lens focused on big-picture trends, GEN publication rankings and widely discussed areas of industry need. The development and growth of the BHCR is also a story that supports the life […]

Comments Off on BioBuzz: Pat Larrabee is Building the Biotech Infrastructure in the Capital Region and has been for Nearly 25 Years – Here’s What’s Next… Continue Reading →